Incretin receptor agonists: a research overview
How GIP, GLP-1, and glucagon receptor agonist peptides are characterised in the published literature, and what the evidence base does and does not establish.
Research use only. For laboratory research use only. Not a drug, food, cosmetic, or medical device. Not for human or veterinary use, diagnostic use, or any form of administration.
Research overview
Incretin receptor agonists are synthetic peptides designed to bind one or more of the GIP, GLP-1, and glucagon receptors. The literature spans receptor-binding assays, cell-based signalling work, rodent pharmacology, and randomised human clinical trials of specific investigational products.
Molecular characteristics
These are single-chain synthetic peptides, commonly modified with fatty-acid side chains that extend circulating half-life via albumin binding. Sequence, modification, and purity determine receptor selectivity profiles reported in the literature.
Areas examined in published research
Receptor binding and selectivity, downstream cAMP signalling, energy expenditure and substrate handling in rodent models, glycaemic endpoints, and tolerability profiles in clinical trial populations.
Study designs and model systems
Reported work includes transfected cell lines expressing individual receptors, primary islet preparations, diet-induced obese rodent models, and randomised, double-blind, placebo-controlled human trials.
In vitro evidence
Cell-based assays are used to establish potency and relative selectivity across the three receptors. These assays characterise the molecule, not any particular supplied lot.
Animal-model evidence
Rodent studies report changes in food intake, body composition, and glycaemic measures. Species differences in incretin biology limit direct extrapolation.
Human clinical research
Randomised trials have been conducted with investigational products manufactured to clinical standards. Those results describe the investigational product studied under trial conditions. They say nothing about research-grade material supplied for laboratory use, and Batch One makes no claim on their basis.
Limitations
Clinical trial findings apply to investigational products manufactured and administered under trial protocols. Material supplied by Batch One is research grade and is not equivalent. Preclinical findings are model-specific.
Regulatory status
These compounds are not approved for sale as drugs in this form. Material supplied by Batch One is not a drug, is not manufactured to pharmaceutical standards, and is for laboratory research use only.
References
- Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.
Human clinical · Randomised phase 2 trial in adults · source pending verification
Reports outcomes of a randomised phase 2 clinical trial of retatrutide. Summarised here as published; Batch One makes no claim about the material it supplies on the basis of this trial.
Limitations: Phase 2 trial with a defined study population and duration. Trial-grade investigational material is not equivalent to research-grade material supplied for laboratory use.
- Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine.
Human clinical · Randomised phase 3 trial in adults · source pending verification
Randomised phase 3 trial of tirzepatide. Included for accurate characterisation of the published human evidence base for the compound class.
Limitations: Findings apply to the investigational product studied under trial conditions only.
Referenced materials
Last reviewed 2026-08-14 · Research content reviewer, Batch One